logo
AAT Bioquest

Tyrosine-protein kinase receptor FLT3 Inhibitors (IC50, Ki)

Structure
Compound Name
Standard Type
Standard Values (in nM)
QuizartinibIC5039.0 [1]
StaurosporineIC501.0 [1]
SorafenibIC5033.0 [1]
SunitinibIC509.9 [1]
N-[4-[(4-Methylpiperazin-1-yl)methyl]phenyl]-4-(thieno[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamideIC501.85 [1]
TandutinibIC50102.0 [1]
4-[(2-Methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino]-N-(4-piperazin-1-ylphenyl)-1H-pyrazole-5-carboxamideIC508.74 [1]
LinifanibIC507.0 [1]
3-[1-[3-(Dimethylamino)propyl]pyrazol-4-yl]-7-(1H-pyrazol-4-yl)-5H-indeno[1,2-b]indol-10-oneIC504.0 [1]
CabozantinibIC506.0 [1], 11.3 [2], 25.0 [3], 7500.0 [4]
TozasertibIC5030.0 [1]
TozasertibKi30.0 [1]
LestaurtinibIC501.5 [1], 2.5 [2], 2.6 [3], 5.0 [4], 8.2 [5]
ForetinibIC503.6 [1], 5.58 [2]
3-N-[4-(4-Morpholin-4-ylcyclohexyl)phenyl]-1-pyridin-2-yl-1,2,4-triazole-3,5-diamineIC501.3 [1]
3-N-[4-(4-Morpholin-4-ylcyclohexyl)phenyl]-1-pyridin-2-yl-1,2,4-triazole-3,5-diamineKi0.17 [1], 2.0 [2], 5.0 [3]
1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl]ureaIC501.0 [1], 3.0 [2], 4.0 [3], 39.0 [4]
1-(5-Ethyl-1,2-oxazol-3-yl)-3-[4-[2-[[6-(4-ethylpiperazin-1-yl)-2-methylpyrimidin-4-yl]amino]-1,3-thiazol-5-yl]phenyl]ureaIC5010.0 [1], 38.0 [2]
(4S,6Z,9S,10S)-9,10,18-Trihydroxy-16-methoxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,15,17-tetraene-2,8-dioneIC501.59 [1], 11.0 [2], 36.0 [3], 62.0 [4]
3-(1H-Indol-3-yl)-4-(3,4,5-trimethoxyphenyl)pyrrole-2,5-dioneIC5018.0 [1], 166.0 [2], 270.0 [3]
Flt-3 Inhibitor IIIC5033.0 [1], 40.0 [2], 100.0 [3]
1-[(5,6-Dimethyl-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]-3-methylpyrrole-2,5-dioneIC5011.38 [1], 13.68 [2]
1-[[6-(Hydroxymethyl)-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]-3-methylpyrrole-2,5-dioneIC5091.23 [1], 112.0 [2], 156.0 [3], 175.0 [4]
4-N-(3,5-Dimethoxyphenyl)-4-N-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-1-N-propan-2-ylcyclohexane-1,4-diamineIC503801.89 [1], 5370.32 [2], 8511.38 [3], 10000.0 [4]
3-Methyl-1-[[5-methyl-6-[4-[2-(methylamino)ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dioneIC508.03 [1], 10.15 [2], 11.1 [3]
PalbociclibIC503000.0 [1], 3480.0 [2], 10000.0 [3]
MidostaurinIC5013.0 [1], 15.0 [2], 37.0 [3]
Nvp-tae 684IC503.0 [1], 554.0 [2], 3000.0 [3]
BemcentinibIC500.9 [1], 2.0 [2], 6.0 [3]
(16E)-14-Methyl-20-oxa-5,7,14,27-tetrazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaeneIC5021.0 [1], 42.0 [2], 56.0 [3]
4-Methyl-5-(2-((4-morpholinophenyl)amino)-pyrimidin-4-yl)thiazol-2-amineIC5025.12 [1], 88.0 [2]
4-Methyl-5-(2-((4-morpholinophenyl)amino)-pyrimidin-4-yl)thiazol-2-amineKi44.0 [1]
4-[2-(Butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-olIC500.35 [1], 0.8 [2], 14.0 [3]
Amg-925IC501.0 [1], 1.5 [2], 5.0 [3]
4-[5-[4-[(4-Methyl-1,4-diazepan-1-yl)methyl]phenyl]-2-[[(2S)-pentan-2-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-olIC502.5 [1], 39.0 [2], 70.0 [3]
Flt3-IN-3IC503.0 [1], 8.0 [2], 13.0 [3]
2-N-(4-Aminocyclohexyl)-9-cyclopentyl-6-N-(4-morpholin-4-ylphenyl)purine-2,6-diamineIC502.0 [1], 7.0 [2], 21.0 [3]
Propan-2-yl 2-hydroxy-4-methoxy-6-[(E)-3-(prop-2-enoylamino)prop-1-enyl]benzoateIC5030000.0 [1]
Propan-2-yl 4-[2-(4-fluorophenyl)ethoxy]-2-hydroxy-6-[(E)-3-(prop-2-enoylamino)prop-1-enyl]benzoateIC508310.0 [1], 30000.0 [2]
Propan-2-yl 2-hydroxy-4-(3-morpholin-4-ylpropoxy)-6-[(E)-3-(prop-2-enoylamino)prop-1-enyl]benzoateIC50500.0 [1], 2810.0 [2], 9610.0 [3]
Propan-2-yl 2-[(E)-3-[[(E)-4-(diethylamino)but-2-enoyl]amino]prop-1-enyl]-4-[2-(4-fluorophenyl)ethoxy]-6-hydroxybenzoateIC501110.0 [1], 30000.0 [2]
Propan-2-yl 2-[(E)-3-(ethenylsulfonylamino)prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC502250.0 [1], 10820.0 [2], 12030.0 [3]
Propan-2-yl 2-[3-(ethenylsulfonylamino)propyl]-6-hydroxy-4-(2-morpholin-4-ylethoxy)benzoateIC504230.0 [1], 18590.0 [2], 30000.0 [3]
(4-Bromophenyl)methyl 2-[(E)-3-(ethenylsulfonylamino)prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC5030000.0 [1]
(4-Fluorophenyl)methyl 2-[(E)-3-(ethenylsulfonylamino)prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC5030000.0 [1]
Cyclohexylmethyl 2-[(E)-3-(ethenylsulfonylamino)prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC5030000.0 [1]
2-Phenylpropyl 2-[(E)-3-(ethenylsulfonylamino)prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC5030000.0 [1]
Propan-2-yl 2-acetyloxy-6-[(E)-3-(2,5-dioxopyrrol-1-yl)prop-1-enyl]-4-methoxybenzoateIC503370.0 [1], 3610.0 [2], 21800.0 [3]
Propan-2-yl 2-[(E)-3-(2,5-dioxopyrrol-1-yl)prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC50540.0 [1], 1340.0 [2], 9790.0 [3]
Propan-2-yl 2-[3-(2,5-dioxopyrrol-1-yl)propyl]-6-hydroxy-4-methoxybenzoateIC50430.0 [1], 3030.0 [2], 13180.0 [3]
Propan-2-yl 2-[(E)-3-(2,5-dioxopyrrol-1-yl)prop-1-enyl]-6-hydroxy-4-(3-morpholin-4-ylpropoxy)benzoateIC50150.0 [1], 940.0 [2], 980.0 [3]
Propan-2-yl 2-[3-(2,5-dioxopyrrol-1-yl)propyl]-6-hydroxy-4-(2-morpholin-4-ylethoxy)benzoateIC50580.0 [1], 810.0 [2], 8870.0 [3]
(4-Bromophenyl)methyl 2-[(E)-3-(2,5-dioxopyrrol-1-yl)prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC501740.0 [1], 1900.0 [2], 30000.0 [3]
(4-Fluorophenyl)methyl 2-[(E)-3-(2,5-dioxopyrrol-1-yl)prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC50950.0 [1], 1640.0 [2], 30000.0 [3]
Cyclohexylmethyl 2-[(E)-3-(2,5-dioxopyrrol-1-yl)prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC502100.0 [1], 2690.0 [2], 30000.0 [3]
2-Phenylpropyl 2-[(E)-3-(2,5-dioxopyrrol-1-yl)prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC503010.0 [1], 5200.0 [2], 30000.0 [3]
Propan-2-yl 2-[(E)-3-[[(E)-but-2-enoyl]amino]prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC5030000.0 [1]
Propan-2-yl 2-[(E)-3-[[(E)-but-2-enoyl]amino]prop-1-enyl]-4-[2-(4-fluorophenyl)ethoxy]-6-hydroxybenzoateIC5030000.0 [1]
[(2S)-3-Methylbutan-2-yl] 2-hydroxy-4-methoxy-6-[(E)-3-(prop-2-enoylamino)prop-1-enyl]benzoateIC5030000.0 [1]
[(2S)-3-Methylbutan-2-yl] 2-[(E)-3-[[(E)-4-(diethylamino)but-2-enoyl]amino]prop-1-enyl]-6-hydroxy-4-methoxybenzoateIC5030000.0 [1]
2-N-(5-Aminopentyl)-9-cyclopentyl-6-N-[4-(morpholin-4-ylmethyl)phenyl]purine-2,6-diamineIC505.0 [1], 25.0 [2], 65.0 [3]
2-N-(4-Aminocyclohexyl)-9-cyclopentyl-6-N-(4-pyrrolidin-1-ylphenyl)purine-2,6-diamineIC503.0 [1], 11.0 [2], 21.0 [3]
2-N-(4-Aminobutyl)-9-cyclopentyl-6-N-(4-morpholin-4-ylphenyl)purine-2,6-diamineIC504.0 [1], 7.0 [2], 23.0 [3]
2-N-(6-Aminohexyl)-9-cyclopentyl-6-N-[4-(morpholin-4-ylmethyl)phenyl]purine-2,6-diamineIC5010.0 [1], 21.0 [2], 69.0 [3]
2-N-(4-Aminobutyl)-9-cyclopentyl-6-N-[4-(morpholin-4-ylmethyl)phenyl]purine-2,6-diamineIC501.0 [1], 5.0 [2], 6.0 [3]
1-(Cyclopentylmethyl)-N-methyl-3-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]pyrazolo[3,4-d]pyrimidin-6-amineIC508.0 [1], 12.0 [2], 30.0 [3]
2-N-Benzyl-9-cyclopentyl-6-N-[4-(morpholin-4-ylmethyl)phenyl]purine-2,6-diamineIC5026.0 [1], 83.0 [2], 624.0 [3]
2-N-(4-Aminobutyl)-9-cyclopentyl-6-N-[4-(4-ethylpiperazin-1-yl)phenyl]purine-2,6-diamineIC501.0 [1], 3.0 [2], 13.0 [3]
1-(Cyclopentylmethyl)-N-methyl-3-[4-(4-methylpiperazin-1-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-amineIC501.4 [1], 4.0 [2], 11.0 [3]
2-N-(4-Aminocyclohexyl)-9-cyclopentyl-6-N-[4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl]purine-2,6-diamineIC504.0 [1], 13.0 [2], 28.0 [3]
2-N-(4-Aminocyclohexyl)-6-N-(4-bromophenyl)-9-cyclopentylpurine-2,6-diamineIC504.0 [1], 16.0 [2]
2-N-(4-Aminocyclohexyl)-9-cyclopentyl-6-N-[4-(4-ethylpiperazin-1-yl)phenyl]purine-2,6-diamineIC502.0 [1], 3.0 [2], 10.0 [3]
N-[5-[6-(Methylamino)pyrazin-2-yl]-2-oxo-1H-pyridin-3-yl]-4-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]benzamideKi20.0 [1], 1000.0 [2]
5-Fluoro-3-[[4-[2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethoxy]-3-methylazulen-1-yl]methylidene]-1H-indol-2-oneIC5067.0 [1], 70.0 [2], 98.0 [3]
N-[5-[4-[[(5-Tert-butyl-1,2-oxazol-3-yl)carbamoylamino]methyl]phenyl]-1H-pyrazol-3-yl]-4-(2-morpholin-4-ylethoxy)benzamideIC501.0 [1], 18.0 [2]
NintedanibIC5026.0 [1]
CeritinibIC5060.0 [1], 3143.0 [2]
DovitinibIC501.0 [1], 3.0 [2]
PexidartinibIC505.0 [1], 130.0 [2]
6,7-Dimethyl-2-phenylquinoxalineIC501100.0 [1]
CrenolanibIC503.0 [1], 4.0 [2]
Bms-777607IC5016.0 [1], 18.0 [2]
1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)ureaIC5010.0 [1]
ErdafitinibIC505.0 [1], 10000.0 [2]
KW-2449IC5013.1 [1], 14.8 [2]
3-(1H-Indol-5-yl)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrrolo[2,3-b]pyridineIC504.0 [1], 560.0 [2]
JNJ-28312141 free baseIC5021.0 [1], 30.0 [2]
Flt-3 inhibitorIC5042.0 [1], 2900.0 [2]
CID 44545852IC50134.0 [1], 10000.0 [2]
MivavotinibIC504.6 [1], 22.0 [2]
TafetinibIC501.3 [1], 5.0 [2]
2-(4-((6,7-Dimethoxyquinazolin-4-yl)oxy)phenyl)-N-(1-isopropyl-1H-pyrazol-4-yl)acetamideIC507.0 [1]
11-(2-Pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaeneIC506.0 [1], 22.0 [2]
2-(6,7-Dimethoxyquinazolin-4-yl)sulfanyl-1,3-thiazoleIC507.0 [1]
CID 56673651IC5011.0 [1], 13.0 [2]
2-[4-[(6,7-Dimethoxyquinazolin-4-yl)amino]phenyl]-N-(1-propan-2-ylpyrazol-4-yl)acetamideIC5020.0 [1]
N-Phenyl-1H-indazole-3-carboxamideIC50350.0 [1], 417.0 [2]
2-[[4-[4-Amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl]amino]acetic acidIC5028.0 [1], 32.0 [2]
(2S)-2-[[4-[4-Amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl]amino]-4-methylpentanoic acidIC5014.0 [1], 23.0 [2]
3-Methyl-1-[(6-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dioneIC5014.66 [1], 16.78 [2]



References

This online tool may be cited as follows

MLA

"Quest Database™ Tyrosine-protein kinase receptor FLT3 Inhibitors (IC50, Ki)." AAT Bioquest, Inc.22 Dec2024https://www.aatbio.com/data-sets/tyrosine-protein-kinase-receptor-flt3-inhibitors-ic50-ki.

APA

AAT Bioquest, Inc. (2024December 22). Quest Database™ Tyrosine-protein kinase receptor FLT3 Inhibitors (IC50, Ki). AAT Bioquest. https://www.aatbio.com/data-sets/tyrosine-protein-kinase-receptor-flt3-inhibitors-ic50-ki.
BibTeXEndNoteRefMan